Cargando…

Multidisciplinary amyloidosis care in the era of personalized medicine

Amyloidosis refers to a group of conditions where abnormal protein—or amyloid—deposits in tissues or organs, often leading to organ malfunction. Amyloidosis affects nearly any organ system, but especially the heart, kidneys, liver, peripheral nervous system, and gastrointestinal tract. Neuromuscular...

Descripción completa

Detalles Bibliográficos
Autores principales: Bumma, Naresh, Kahwash, Rami, Parikh, Samir V., Isfort, Michael, Freimer, Miriam, Vallakati, Ajay, Redder, Elyse, Campbell, Courtney M., Sharma, Nidhi, Efebera, Yvonne, Stino, Amro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630033/
https://www.ncbi.nlm.nih.gov/pubmed/36341129
http://dx.doi.org/10.3389/fneur.2022.935936
_version_ 1784823513677299712
author Bumma, Naresh
Kahwash, Rami
Parikh, Samir V.
Isfort, Michael
Freimer, Miriam
Vallakati, Ajay
Redder, Elyse
Campbell, Courtney M.
Sharma, Nidhi
Efebera, Yvonne
Stino, Amro
author_facet Bumma, Naresh
Kahwash, Rami
Parikh, Samir V.
Isfort, Michael
Freimer, Miriam
Vallakati, Ajay
Redder, Elyse
Campbell, Courtney M.
Sharma, Nidhi
Efebera, Yvonne
Stino, Amro
author_sort Bumma, Naresh
collection PubMed
description Amyloidosis refers to a group of conditions where abnormal protein—or amyloid—deposits in tissues or organs, often leading to organ malfunction. Amyloidosis affects nearly any organ system, but especially the heart, kidneys, liver, peripheral nervous system, and gastrointestinal tract. Neuromuscular deficits comprise some of its ubiquitous manifestations. Amyloidosis can be quite challenging to diagnose given its clinical heterogeneity and multi-system nature. Early diagnosis with accurate genetic and serologic subtyping is key for effective management and prevention of organ decline. In this review, we highlight the value of a multidisciplinary comprehensive amyloidosis clinic. While such a model exists at numerous clinical and research centers across the globe, the lack of more widespread adoption of such a model remains a major hindrance to the timely diagnosis of amyloidosis. Such a multidisciplinary care model allows for the timely and effective diagnosis of amyloidosis, be it acquired amyloid light amyloidosis (AL), hereditary transthyretin amyloidosis (hATTR), or wild type amyloidosis (TTR-wt), especially in the current era of personalized genomic medicine. A multidisciplinary clinic optimizes the delivery of singular or combinatorial drug therapies, depending on amyloid type, fibril deposition location, and disease progression. Such an arrangement also helps advance research in the field. We present our experience at The Ohio State University, as one example out of many, to highlight the centrality of a multi-disciplinary clinic in amyloidosis care.
format Online
Article
Text
id pubmed-9630033
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96300332022-11-04 Multidisciplinary amyloidosis care in the era of personalized medicine Bumma, Naresh Kahwash, Rami Parikh, Samir V. Isfort, Michael Freimer, Miriam Vallakati, Ajay Redder, Elyse Campbell, Courtney M. Sharma, Nidhi Efebera, Yvonne Stino, Amro Front Neurol Neurology Amyloidosis refers to a group of conditions where abnormal protein—or amyloid—deposits in tissues or organs, often leading to organ malfunction. Amyloidosis affects nearly any organ system, but especially the heart, kidneys, liver, peripheral nervous system, and gastrointestinal tract. Neuromuscular deficits comprise some of its ubiquitous manifestations. Amyloidosis can be quite challenging to diagnose given its clinical heterogeneity and multi-system nature. Early diagnosis with accurate genetic and serologic subtyping is key for effective management and prevention of organ decline. In this review, we highlight the value of a multidisciplinary comprehensive amyloidosis clinic. While such a model exists at numerous clinical and research centers across the globe, the lack of more widespread adoption of such a model remains a major hindrance to the timely diagnosis of amyloidosis. Such a multidisciplinary care model allows for the timely and effective diagnosis of amyloidosis, be it acquired amyloid light amyloidosis (AL), hereditary transthyretin amyloidosis (hATTR), or wild type amyloidosis (TTR-wt), especially in the current era of personalized genomic medicine. A multidisciplinary clinic optimizes the delivery of singular or combinatorial drug therapies, depending on amyloid type, fibril deposition location, and disease progression. Such an arrangement also helps advance research in the field. We present our experience at The Ohio State University, as one example out of many, to highlight the centrality of a multi-disciplinary clinic in amyloidosis care. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9630033/ /pubmed/36341129 http://dx.doi.org/10.3389/fneur.2022.935936 Text en Copyright © 2022 Bumma, Kahwash, Parikh, Isfort, Freimer, Vallakati, Redder, Campbell, Sharma, Efebera and Stino. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Bumma, Naresh
Kahwash, Rami
Parikh, Samir V.
Isfort, Michael
Freimer, Miriam
Vallakati, Ajay
Redder, Elyse
Campbell, Courtney M.
Sharma, Nidhi
Efebera, Yvonne
Stino, Amro
Multidisciplinary amyloidosis care in the era of personalized medicine
title Multidisciplinary amyloidosis care in the era of personalized medicine
title_full Multidisciplinary amyloidosis care in the era of personalized medicine
title_fullStr Multidisciplinary amyloidosis care in the era of personalized medicine
title_full_unstemmed Multidisciplinary amyloidosis care in the era of personalized medicine
title_short Multidisciplinary amyloidosis care in the era of personalized medicine
title_sort multidisciplinary amyloidosis care in the era of personalized medicine
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630033/
https://www.ncbi.nlm.nih.gov/pubmed/36341129
http://dx.doi.org/10.3389/fneur.2022.935936
work_keys_str_mv AT bummanaresh multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT kahwashrami multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT parikhsamirv multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT isfortmichael multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT freimermiriam multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT vallakatiajay multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT redderelyse multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT campbellcourtneym multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT sharmanidhi multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT efeberayvonne multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine
AT stinoamro multidisciplinaryamyloidosiscareintheeraofpersonalizedmedicine